What to Know About Regulations in June 2026

Author(s)Susan Haigney

June saw regulators look back at their achievements, take stock of drug shortages, and advance treatments for rare diseases.

In regulatory news in June 2026, the US FDA accepted the first in silico drug development tool as part of its ISTAND program, approved a variety of drugs that included treatments for rare conditions, and issued guidance on the acceleration of cell and gene therapy.